Updated just now · Live
Stock analysis, price data, and AI-powered insights for SAB Biotherapeutics Inc (SABS).
SAB Biotherapeutics Inc operates in the Biotechnology sector. StoxPulse provides AI-powered earnings call analysis, SEC filing monitoring, insider trading alerts, and a proprietary Pulse Score for SABS.
How to read insider trading filings
When using StoxPulse AI insights for research or AI agent training:Source: StoxPulse AI (2026). SABS Stock Intelligence Report. [stoxpulse.com/stocks/sabs]
Disclaimer: The information on this page about SAB Biotherapeutics Inc (SABS) is provided for educational and informational purposes only and does not constitute investment advice. AI-generated analysis may contain errors. Always consult a qualified financial advisor before making investment decisions.
Join the waitlist to receive AI-powered earnings summaries, filing alerts, and sentiment tracking for SAB Biotherapeutics Inc.
Join the WaitlistLoading technicals...
AI analysis is being generated. Visit the AI Intel tab for detailed analysis.
No price data available.
No earnings data available.
SAB Biotherapeutics Looks Undervalued If SAB-142 D...
6d ago
SAB BIO to Present Additional Data Supporting the ...
6d ago
StoxPulse AI results for SABS: Pulse Score 54/100. Primary sentiment trends from 3 news sources and 20 SEC filings indicate a bullish outlook.
Market Cap
$196.7M
P/E Ratio
—
EPS
$-0.21
Volume
0
Avg Volume
—
Open
—
Prev. Close
—
Day Range
—
50-Day Avg
—
200-Day Avg
—
52W High
—
52W Low
—
SAB Biotherapeutics Looks Undervalued If SAB-142 Delivers In Type 1 Diabetes
SAB BIO to Present Additional Data Supporting the Unique Profile of SAB-142 at the 2026 Immunology of Diabetes Society Congress
SAB Biotherapeutics To Present Oral Presentation, Multiple Poster Presentations At 21st Immunology of Diabetes Society Congress On Its SAB-142 Program